PharmiWeb.Jobs

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross domestic product. McKinsey & Co. follows suit, noting AI could generate 30% efficiency gains and cost savings in the pharmaceutical sector and trigger financial gains of up to $110 billion annually.

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the appointment of Dr. Mikael Dolsten to its board of directors.

A little over a year ago, a Renton man was told there was only one thing left to decide. Did he want to die at home, or in the hospital? He's still living.

During a health-focused event in New York on Tuesday, Google announced that it's developing a collection of "open" AI models for drug discovery called

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

Johnson & Johnson signed a multibillion-dollar contract with ChemImage in 2019. The two companies will face off in court next week.

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases offering training for it.